Alvotech Attacks AbbVie Over Adalimumab

Launches US Legal Challenge Over Humira Patent ‘Monopoly’

12 May 2021

Alvotech has launched a US legal challenge over intellectual property around AbbVie’s Humira, claiming that the company enjoys a “wrongful monopoly” on the top-selling arthritis treatment for which the biosimilars company is developing a high-concentration adalimumab rival.

Danger Minefield Sign — Alvotech has cited the “minefield of IP” around Humira • Source: Alamy

Alvotech has launched a legal challenge to what it says is AbbVie’s “wrongful monopoly” on its Humira (adalimumab) biologic brand in the US, citing a “minefield of intellectual property” of “questionable validity” that surrounds the top-selling arthritis treatment.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

BGMA Becomes Medicines UK

01 May 2025

• By Dave Wallace

The UK generics and biosimilars industry will now be represented by Medicines UK, the new name for the former British Generic Manufacturers Association.

J&J Denied Injunction Over Private-Label Ustekinumab In US

01 May 2025

• By Dave Wallace

Stelara originator J&J has been denied in its initial attempt to prevent Samsung Bioepis and ustekinumab biosimilar partner Sandoz from selling a private-label version of the product through a PBM in the US.